Skip to main content

and
Your search also matched 2 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Interleukin 1β mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells

Include preview-only content
  1. Article

    Open Access

    EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205

    Expression of epithelial cell adhesion molecule (EpCAM) is deregulated in epithelial malignancies. Beside its role in cell adhesion, EpCAM acts as signalling molecule with tumour-promoting functions. Thus, EpC...

    P Massoner, T Thomm, B Mack, G Untergasser, A Martowicz in British Journal of Cancer (2014)

  2. Article

    Open Access

    Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer

    Insulin-like growth factor (IGF) and insulin (INS) proteins regulate key cellular functions through a complex interacting multi-component molecular network, known as the IGF/INS axis. We describe how dynamic a...

    P Massoner, M Ladurner-Rennau, I E Eder, H Klocker in British Journal of Cancer (2010)

  3. Article

    Open Access

    Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells

    Interactions between polypeptide growth factors and the androgen receptor (AR) are important for regulation of cellular events in carcinoma of the prostate. Basic fibroblast growth factor (bFGF), the prototype...

    M V Cronauer, C Nessler-Menardi, H Klocker, K Maly, A Hobisch in British Journal of Cancer (2000)

  4. Article

    Open Access

    Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

    Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists. In order to investigate the mechanisms relevant to the development of therapy-resistant tumours, we establish...

    Z Culig, J Hoffmann, M Erdel, I E Eder, A Hobisch, A Hittmair in British Journal of Cancer (1999)